secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vanda Pharmaceuticals Inc. (VNDA)
CIK:        0001347178
Form:       8-K
Filed at:   2024-09-19T23:59:59+00:00
Accession:  0001193125-24-221784
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA issues Complete Response Letter declining Vanda's tradipitant NDA for gastroparesis
--------------------------------------------------------------------------------

- FDA declined to approve tradipitant for gastroparesis on Sept 18, 2024; issued CRL citing need for additional studies.
- FDA action was delayed by over 185 days, Vanda says fails requirements of FDCA.
- Vanda believes application met substantial evidence standard and plans to continue pursuing approval.
- Separate NDA for tradipitant in prevention of vomiting from motion sickness planned later this year.
- Expanded access program continues for several dozen gastroparesis patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347178/000119312524221784/0001193125-24-221784-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347178/000119312524221784/d809647d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-221784

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer